Publications by authors named "R A Walgren"
Article Synopsis
- Bruton tyrosine kinase inhibitors (BTKi) have significantly improved treatment for B-cell malignancies, but many patients stop using them due to side effects, with cardiac issues being the most common reason for discontinuation.* -
- The BRUIN study tested pirtobrutinib, a new non-covalent BTKi, on 127 patients who were intolerant to previous BTKi treatments, finding that many experienced fewer or no cardiac issues while showing a high overall response rate.* -
- Results indicated pirtobrutinib had a median time on treatment of 15.3 months, with notable side effects like fatigue and neutropenia; overall, it proved to be a safe and effective alternative for
Article Synopsis
- Pirtobrutinib is a new, selective Bruton tyrosine kinase inhibitor (BTKi) that shows promise for patients with mantle-cell lymphoma (MCL) who have previously been treated with covalent BTK inhibitors due to a generally poor prognosis.
- In a phase I/II trial, the drug demonstrated an overall response rate of 57.8% with a median duration of response lasting 21.6 months, indicating effectiveness in this challenging patient group.
- The treatment was well tolerated, with only a small percentage of patients discontinuing therapy due to adverse events such as fatigue and diarrhea, suggesting it may be a viable option for patients with previously recurRent MCL.
This retrospective study using the nationwide de-identified Flatiron Health electronic health record-derived database was designed to evaluate clinical outcomes among patients with chronic lymphocytic leukemia (CLL) who previously received both a covalent Bruton's tyrosine kinase inhibitor (cBTKi) and B-cell lymphoma 2 inhibitor (BCL2i) in a real-world setting. Outcomes for the immediate next line of therapy following the latter of the cBTKi or BCL2i treatment included: real-world response rate of 34.4% (using methods most consistent with clinical trials); median duration of real-world response of 13.
View Article and Find Full Text PDFArticle Synopsis
- Bruton tyrosine kinase (BTK) is important for treating B-cell cancers, but existing covalent inhibitors have issues with side effects and resistance mutations.
- Pirtobrutinib is a new, selective, noncovalent BTK inhibitor that effectively targets BTK and its mutations without the same drawbacks as current treatments.
- Preclinical studies show that pirtobrutinib not only inhibits B-cell lymphoma growth and signaling but also demonstrates improved selectivity and stability, leading to Phase 3 clinical trials for various B-cell malignancies.
Purpose: There remains a lack of consensus among experts regarding the optimal therapeutic approach for Mantle cell lymphoma (MCL) after failure of covalent Bruton Tyrosine Kinase inhibitor (cBTKi)-based therapy. This study was designed to examine patient characteristics, current treatment patterns, and clinical outcomes using a real-world database to evaluate how MCL is currently managed post-cBTKi therapy in the U.S.
View Article and Find Full Text PDF